Jonathan W Goldman

Jonathan W Goldman

UNVERIFIED PROFILE

Are you Jonathan W Goldman?   Register this Author

Register author
Jonathan W Goldman

Jonathan W Goldman

Publications by authors named "Jonathan W Goldman"

Are you Jonathan W Goldman?   Register this Author

47Publications

3065Reads

43Profile Views

Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.

Lung Cancer 2019 Sep 21;135:104-109. Epub 2019 May 21.

David Geffen School of Medicine at University of California Los Angeles, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.05.022DOI Listing
September 2019

Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story.

J Thorac Oncol 2019 Feb;14(2):160-162

David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.009DOI Listing
February 2019

A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment.

J Thorac Oncol 2018 09 5;13(9):1284-1293. Epub 2018 Jul 5.

Department of Psychology, University of California-Los Angeles, Los Angeles, California; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California; Department of Psychiatry/Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California; Cousins Center for Psychoneuroimmunology, University of California-Los Angeles, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291203PMC
September 2018

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.

BMC Nephrol 2018 08 20;19(1):210. Epub 2018 Aug 20.

Department of Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Connie Frank Kidney Transplant Center, 200 Medical Plaza, Ste 565, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882
Publisher Site
http://dx.doi.org/10.1186/s12882-018-1003-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102916PMC
August 2018

Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.

Radiology 2018 04 12;287(1):326-332. Epub 2017 Dec 12.

From the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2017170347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276060PMC
April 2018

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).

Clin Lung Cancer 2018 01 20;19(1):e19-e28. Epub 2017 Jun 20.

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761337PMC
January 2018

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.

Ther Adv Med Oncol 2018 22;10:1758834017751634. Epub 2018 Jan 22.

Division of Dermatology 52-121 CHS, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017751634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784551PMC
January 2018

Biophysical isolation and identification of circulating tumor cells.

Lab Chip 2017 04;17(8):1452-1461

Department of Bioengineering, University of California, Los Angeles, 410 Westwood Plaza, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c7lc00038cDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507599PMC
April 2017

Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

Oncologist 2016 Nov 29;21(11):1326-1336. Epub 2016 Jul 29.

Endocrinology Medical Group of Orange County, Inc., Orange, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189614PMC
November 2016

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2969-79. Epub 2016 Jun 27.

Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.66.9861
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.66.9861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569693PMC
September 2016

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2980-7. Epub 2016 Jun 27.

Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569692PMC
September 2016

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Cancer Chemother Pharmacol 2016 Feb;77(2):439

Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL, 34232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2890-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969883PMC
February 2016

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Cancer Chemother Pharmacol 2015 Nov 14;76(5):925-32. Epub 2015 Sep 14.

Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL, 34232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2850-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612319PMC
November 2015

High efficiency vortex trapping of circulating tumor cells.

Biomicrofluidics 2015 Nov 17;9(6):064116. Epub 2015 Dec 17.

Vortex Biosciences, Inc. , 1455 Adams Drive, Menlo Labs, Suite 2010, Menlo Park, California 94025, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.4937895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684572PMC
November 2015

MET-Mutated NSCLC with Major Response to Crizotinib.

J Thorac Oncol 2015 May;10(5):e33-4

The David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, California The David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000491DOI Listing
May 2015

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1700-9

From Massachusetts General Hospital (L.V.S., R.S.H., J.L., Z.P.), Harvard Medical School (L.V.S., G.R.O., R.S.H., Z.P.), and Dana-Farber Cancer Institute (G.R.O.) - all in Boston; the Drug Development Department, Université Paris-Sud, Gustave Roussy Cancer Campus (J.-C.S.), and Institut Gustave Roussy (A.V.), Villejuif - both in France; the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G., E.B.G., M.A.M., S.N.), and Stanford Cancer Institute, Stanford University, Stanford (H.A.W., J.W.N.) - both in California; the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit (S.M.G., C.G., A.J.W.); University of Texas M.D. Anderson Cancer Center, Houston (V.P.); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); the Medical University of Gdansk, Gdansk, Poland (R.D.); the University of Colorado (D.L.A., D.R.C.) and University of Colorado Cancer Center (R.C.D.) - both in Aurora; and Clovis Oncology, San Francisco (M.R., C.A.K., S.J.-T., S.L.M., A.R.A.), Boulder, CO (J.I., D.D.), and Cambridge, United Kingdom (L.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1413654DOI Listing
April 2015

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

J Clin Oncol 2015 Mar 20;33(9):1060-6. Epub 2015 Jan 20.

Adil I. Daud, Michelle T. Ashworth, Alan P. Venook, Jennifer A. Grabowsky, and Pamela N. Munster, University of California, San Francisco, San Francisco; Jonathan W. Goldman and Lee S. Rosen, University of California, Los Angeles, Santa Monica, CA; Jonathan Strosberg and Gregory Springett, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David Mendelson, Pinnacle Oncology Hematology, Scottsdale, AZ; and Sabine Loechner, Frances Shanahan, David Parry, Stuart Shumway, Tomoko Freshwater, Christopher Sorge, Soonmo Peter Kang, and Randi Isaacs, Merck, Whitehouse Station, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.5027DOI Listing
March 2015

Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib.

J Clin Oncol 2014 Dec 18;32(34):e114-6. Epub 2014 Feb 18.

University of California, Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.48.7462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876351PMC
December 2014

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.

Cancer 2012 Dec 17;118(23):5903-11. Epub 2012 May 17.

David Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27575DOI Listing
December 2012

Targeting MEK for the treatment of non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(16 Suppl 5):S377-8

UCLA Medical Center, Los Angeles, California 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31826df0bcDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741037PMC
December 2012